FGF-2 Polyclonal Antibody
¥680.00
- 产品信息
商品描述
靶点-Target
NOS3/eNOS
反应性
Human,Mouse,Rat
应用
WB,IHC,IF,IP,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG, Kappa
偶联-Conjugate
Phospho
修饰-Modification
Ser1177
MW(Calculated)
133kD
MW(Observed)
133kD
推荐稀释比
IHC 1:200-1:1000;WB 1:2000-1:10000;IF 1:200-1:1000;ELISA 1:5000-1:20000;IP 1:50-1:200;
组成
PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
纯化工艺
Protein A
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
克隆性
Monoclonal
克隆号
PT0906R
特异性
eNOS (Phospho Ser1177) Monoclonal Antibody detects endogenous levels of eNOS around the phosphorylation site of Ser1177 protein.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):TQsFS
基因名称
NOS3
蛋白名称
Nitric oxide synthase endothelial
别名
NOS3;Nitric oxide synthase;endothelial;Constitutive NOS;cNOS;EC-NOS;Endothelial NOS;eNOS;NOS type III;NOSIII
Organism-1
Human
基因ID-1
4846
SwissProt-1
P29474
Organism-2
Mouse
基因ID-2
18127
SwissProt-2
P70313
Organism-3
Rat
基因ID-3
24600
SwissProt-3
Q62600
背景
Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009],
细胞定位
Cell membrane. Membrane, caveola. Cytoplasm, cytoskeleton. Golgi apparatus. Specifically associates with actin cytoskeleton in the G2 phase of the cell cycle; which is favored by interaction with NOSIP and results in a reduced enzymatic activity.
